Document is current
Any future updates will be listed below
-
Authors
Veatch, Joshua R https://orcid.org/0000-0002-6543-9255
Singhi, Naina
Jesernig, Brenda
Paulson, Kelly G
Zalevsky, Jonathan
Iacucci, Ernesto
Tykodi, Scott S
Riddell, Stanley R
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02983045 at ClinicalTrials.govDocuments that mention this clinical trial
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
https://doi.org/10.1136/jitc-2021-004419
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8<sup>+</sup> T cell cytotoxicity over BEMPEG+RT
https://doi.org/10.1136/jitc-2021-004218
59 Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial
https://doi.org/10.1136/jitc-2021-sitc2021.059
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8<sup>+</sup> T cell responses capable of curing multi-focal cancer
https://doi.org/10.1136/jitc-2019-000464
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study
https://doi.org/10.1136/jitc-2020-sitc2020.0420
Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumab
https://doi.org/10.1136/jitc-2020-001591
-
Funding
Funding for this research was provided by:
Bezos Family
Lembersky Family
National Cancer Institute (K12 CA076930-16A1)
- License Information
